Treatment of moderate-to-severe Atopic dermatitis research hub

LP0162-1335: A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 6 to <12 years) with moderate to-severe atopic dermatitis. - TRAPEDS 1 (TRAlokinumab PEDiatric trial no. 1).

This study, called TRAPEDS 1, is looking at a new medicine called Adtralza for children aged 6 to under 12 who have moderate to severe eczema. We want to see how the medicine works in their bodies and if it's safe.